top of page
About the Trial
Evaluating the efficacy and safety of tozorakimab in symptomatic Chronic Obstructive Pulmonary Disease with a history of exacerbations
Mechanism of Action:
Anti IL-33
Duration of Study
~52 Weeks
Phase
III
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Asvini Kulasingham, RRT
bottom of page